• Home
  • Blog
  • The Most Commonly Used Hormone Therapy Drugs

The Most Commonly Used Hormone Therapy Drugs


The Most Commonly Used Hormone Therapy Drugs

Hormone

The Most Famous Hormone Drugs are:

1- Estradiol 💊

2- Estrogens 💊

3- Testosterone 💊

 

1    

Estradiol

Hormone

  • Brand Names: Alora
  • Therapeutic Category: Estrogen Derivative, Hormone
  • Dosage Forms: Gel, Transdermal/ IM oil/ Patch Transdermal/ Ring, Vaginal/ Tablet oral
  • Use: Labeled Indications:
  • Breast cancer/ Hypoestrogenism/ Osteoporosis prevention/ Prostate cancer/ Vasomotor symptoms associated with menopause/ Vulvar and vaginal atrophy associated with menopause
  • Dosing : Adult : Breast cancer: Males and postmenopausal females: 10 mg 3 times/day
  • Hypoestrogenism: Oral (Estrace): 1 to 2 mg/day
  • Vasomotor symptoms (moderate to severe) associated with menopause: Oral (Estrace): 0.5 to 1 mg once daily
  • Dose Adjustments
  • Renal Impairment: no dosage adjustments
  • Hepatic Impairment:  Contraindicated with hepatic dysfunction or disease
  • Adverse Drug Interaction:
    Edema , hypertension, cerebrovascular accident, deep vein thrombosis, local thrombophlebitis, myocardial infarction, pulmonary thromboembolism, Headache, pain, depression
  • Pharmacodynamics/Kinetics:
  • Absorption: Well absorbed from the gastrointestinal tract, mucous membranes, and the skin
  • Metabolism: Hepatic
  • Excretion: Primarily urine
  • Important Notes:
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer
  • Pregnancy & Lactation: Products approved for use only in postmenopausal women are not appropriate for use in pregnancy/   present in breast milk.
  • Medication Safety issue:

Alora may be confused with Aldara

Elestrin may be confused with alosetron

 

Highly recommend online Marketing tool from SEMRUSH

Hormone

2

Estrogens (Conjugated/Equine, Systemic)

Hormone

 

 

  • Brand Names: Premarin
  • Therapeutic Category: Estrogen Derivative, Hormone
  • Dosage Forms: Oral(Tablet) , Injection (Solution Reconstituted)
  • Use: Labeled Indications:
  • Abnormal uterine bleeding/ Breast cancer/ Hypoestrogenism/ Osteoporosis prevention/ Prostate cancer/ Vasomotor symptoms associated with menopause/ Vulvar and vaginal atrophy associated with menopause
  • Dosing : Adult : Abnormal uterine bleeding: Acute/heavy bleeding: IM, IV: 25 mg, may repeat in 6-12 hours if needed
  • Breast cancer: Oral: Males and postmenopausal females: 10 mg 3 times/day for at least 3 months
  • Hypoestrogenism (female) due to hypogonadism: Oral: 0.3 or 0.625 mg/day given cyclically; dose may be titrated in 6- to 12-month intervals
  • Dose Adjustments
  • Renal Impairment: no dosage adjustments
  • Hepatic Impairment: no dosage adjustments
  • Adverse Drug Interaction:
    Headache/ pain/ Abdominal pain/ Vaginal hemorrhage/  mastalgia/ Back pain / arthralgia
  • Pharmacodynamics/Kinetics:
  • Half-life elimination: Total estrone: 27 hours
  • Metabolism: Hepatic
  • Time to peak, plasma: Total estrone: 7 hours
  • Important Notes:
  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer
  • Pregnancy & Lactation: Use is contraindicated during pregnancy/  Estrogens can be detected in breast milk
  • Medication Safety issue:

Premarin may be confused with Primaxin, Provera, Remeron

 

3

Testosterone

Hormone

 

 

  • Brand Names: Andriol
  • Therapeutic Category: Androgen, Hormone
  • Dosage Forms: Gel (Nasal/ Transdermal)/ Patch Transdermal/ Pellet, Implant / Capsule, Oral/ Solution, Intramuscular
  • Use: Labeled Indications:
  • Breast cancer, metastatic / Delayed puberty/ Hypogonadism, hypogonadotropic/ Hypogonadism
  • Off-Label: Adult: Hormone therapy for transgender males
  • Dosing : Adult : Breast cancer (females): IM : 200 to 400 mg every 2 to 4 weeks.
  • Delayed puberty (males): IM: 50 to 200 mg every 2 to 4 weeks for a limited duration (eg, 4 to 6 months).
  • Hypogonadism (primary) or hypogonadism (hypogonadotropic) (males): IM:Initial: 75 to 100 mg/week or 150 to 200 mg every 2 weeks; dosage range: 50 to 100 mg/week or 100 to 200 mg every 2 weeks
  • Dose Adjustments
  • Renal Impairment: no dosage adjustments
  • Hepatic Impairment: no dosage adjustments
  • Adverse Drug Interaction:
    Hypertension, benign prostatic hypertrophy, Peripheral edema, peripheral vascular disease, Emotional lability
  • Pharmacodynamics/Kinetics:
  • Bioavailability: relative bioavailability decreased 25% when taken with lower fat content meal
  • Half-life elimination: Variable: 10 to 100 minutes; Testosterone cypionate: 8 days
  • Time to peak: IM: 7 days, Oral capsule: 2 to 4 hours
  • Important Notes:
  • Testosterone undecanoate and testosterone enanthate can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events
  • Pregnancy & Lactation: contraindicated during pregnancy./   present in breast milk.
  • Medication Safety issue:

Testosterone may be confused with testolactone

AndroGel 1% may be confused with AndroGel 1.62%

Bio-T-Gel may be confused with T-Gel

Read More:

Copyright ©: All content on FADIC Website, including medical opinion and any other health-related information, and drug Informtation is for informational purposes only